Data from the National Notifiable Diseases Surveillance System and the Quest Diagnostics Health Trends database were used to estimate the incidence of hepatitis C virus (HCV) infection among women ages 15 to 44 years and children ages 2 to 13 years.
The drug was evaluated in three multicenter, phase 3, randomized, double-blind, placebo-controlled trials involving patients with moderately to severely active disease.
Researchers analyzed eight studies with 353 patients to assess the effect of low-molecular-weight heparin or warfarin on recanalization, thrombosis progression, and bleeding.
This week's quiz asks readers to determine the appropriate next step in management for a 60-year-old woman with dull, nonradiating pain that is unrelated to activities.
The guide includes a summary of the latest testing recommendations; diagnostic, billing, and laboratory codes for testing; resources for referrals to HCV-experienced clinicians; and information on patient interactions, education, conversations, and case examples.
Approved use of the drug has been expanded to include treatment of patients with hepatocellular carcinoma who have been treated with sorafenib.
Adjusting for the physicians' detection rate did not alter the differences in risk associated with race/ethnicity, the study noted.
The results support feeding acute pancreatitis patients sooner than recommended by current guidelines, according to the review authors, but an accompanying editorial urged caution in applying the research to practice.
In C difficile infection, adding IV bezlotoxumab to standard antibiotics reduced recurrence at 12 weeks
A commentary in ACP Journal Club noted that it would be reasonable to consider fidaxomicin or bezlotoxumab in patients at high risk for recurrent Clostridium difficile infection or in those for whom recurrence could have devastating consequences.